WILLINGMED

WILLINGMED (Beijing) Co., Ltd. was founded in 2019. The core team comes from well-known research institutions both in China and abroad, such as Tsinghua University and the Chinese Academy of Sciences. With nearly 20 years of deep cultivation in the field of precise detection of pathogenic microorganisms, the company has rich experience in the research and development, registration, production, and operation of molecular diagnostic technologies and products for infectious diseases, as well as third-party medical testing. It also possesses a number of unique core technologies in metagenomic sequencing, microfluidic automation chips, and more. WILLINGMED is a high-tech enterprise focusing on precise diagnosis of infections, with a professional talent team covering scientific research transformation, reagent production, high-end instrument manufacturing, medical testing, bioinformatics, marketing, and other areas. It is committed to becoming a global leader in providing precise medical products and services for infections. Located in the Jinghai Industrial Park in Beijing Economic-Technological Development Area, WILLINGMED owns a research center and a medical testing laboratory. We apply metagenomic high-throughput sequencing technology to pathogen diagnosis, effectively addressing a series of issues such as detection rate, timeliness, and accuracy faced in clinical infection diagnostics, supporting precision medicine for infections, and playing a key role in diagnosing, monitoring, and tracking outbreaks of new infectious diseases. WILLINGMED mainly serves departments such as infectious disease, respiratory, pediatrics, ICU, and oncology in nearly 2,000 tertiary hospitals across China, enabling numerous patients to receive timely and accurate diagnosis and treatment, thereby saving lives and reducing healthcare costs.